Effect of Onabotulinum Toxin A on Substance P and Receptor Neurokinin 1 in the Rat Ventral Prostate

Overview

Journal Andrology (Los Angel)

Publisher Omics Publishing Group

Date 2016 May 5

PMID 27144785

Citations 1

Authors

Omer Onur Cakir

Carol A Podlasek

Douglas Wood

Kevin E McKenna

Kevin T McVary

Affiliations

Soon will be listed here.

Abstract

Introduction: The objective of this work is to examine if sensory innervation impacts lower urinary tract symptoms (LUTS). Onabotulinum toxin A (BoNTA) has been used for the treatment of overactive and neurogenic bladder and as a treatment for LUTS secondary to benign prostatic hyperplasia (BPH). The mechanism of how BoNTA impacts LUTS/BPH is unclear. In rats, BoNTA injection causes prostate denervation, apoptosis and atrophy. In clinical trials reduced prostate size and LUTS are observed inconsistently, suggesting a neurologic component. We will examine if BoNTA treatment inhibits substance P production in sensory nerve fibers in the rat prostate.

Methods: Twenty Sprague Dawley rats were divided into four groups including 1X PBS (control, n=6), 2.5 units Onabotulinum toxin A (BoNTA, n=6), 5 units BoNTA (n=6) injected into both lobes of the ventral prostate (VP) and sham surgery (n=2). Rats were Euthanized after one week. Substance P and its receptor neurokinin 1 localization and quantification were performed by counting the number of stained neurons and nerve bundles, by semi-quantitative immunohistochemical analysis and by western analysis.

Results: Substance P was localized in neuronal axons and bundles in the stroma of the VP but not in the epithelium. Receptor neurokinin 1 was identified in neuronal bundles of the stroma and in columnar epithelium of the VP ducts. Substance P decreased ~90% after BoNTA treatment (p=0.0001) while receptor neurokinin 1 did not change by IHC (p=0.213) or Western (p=0.3675).

Conclusions: BoNTA treatment decreases substance P in the rat VP.

Citing Articles

A Comparison of Effectiveness of Thai Traditional Massage and Tamsulosin in Lower Urinary Tract Symptoms: A Randomized Controlled Trial.

Sinsomboon O, Noppakulsatit P, Tassanarong A, Tungsukruthai P, Sriyakul K J Evid Based Integr Med. 2022; 27:2515690X211068825.

PMID: 35001668 PMC: 8753073. DOI: 10.1177/2515690X211068825.

References

McVary K . BPH: epidemiology and comorbidities. Am J Manag Care. 2006; 12(5 Suppl):S122-8. View

Maria G, Brisinda G, Civello I, Bentivoglio A, Sganga G, Albanese A . Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. Urology. 2003; 62(2):259-64; discussion 264-5. DOI: 10.1016/s0090-4295(03)00477-1. View

Walden P, Marinese D, Srinivasan D, Tzoumaka E, Syyong H, Ford A . Effect of neurokinins on canine prostate cell physiology. Prostate. 2004; 63(4):358-68. DOI: 10.1002/pros.20195. View

Silva J, Pinto R, Carvallho T, Coelho A, Avelino A, Dinis P . Mechanisms of prostate atrophy after glandular botulinum neurotoxin type a injection: an experimental study in the rat. Eur Urol. 2008; 56(1):134-40. DOI: 10.1016/j.eururo.2008.07.003. View

Auffenberg G, Helfand B, McVary K . Established medical therapy for benign prostatic hyperplasia. Urol Clin North Am. 2009; 36(4):443-59, v-vi. DOI: 10.1016/j.ucl.2009.07.004. View

Chuang Y, Huang C, Kang H, Chiang P, DeMiguel F, Yoshimura N . Novel action of botulinum toxin on the stromal and epithelial components of the prostate gland. J Urol. 2006; 175(3 Pt 1):1158-63. DOI: 10.1016/S0022-5347(05)00318-6. View

Ishikawa H, Mitsui Y, Yoshitomi T, MASHIMO K, Aoki S, Mukuno K . Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles. Jpn J Ophthalmol. 2000; 44(2):106-9. DOI: 10.1016/s0021-5155(99)00197-5. View

Doggweiler R, Zermann D, Ishigooka M, Schmidt R . Botox-induced prostatic involution. Prostate. 1998; 37(1):44-50. DOI: 10.1002/(sici)1097-0045(19980915)37:1<44::aid-pros7>3.0.co;2-8. View

Lythgoe C, McVary K . The use of PDE-5 inhibitors in the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Curr Urol Rep. 2013; 14(6):585-94. DOI: 10.1007/s11934-013-0373-2. View

10.

Marberger M, Chartier-Kastler E, Egerdie B, Lee K, Grosse J, Bugarin D . A randomized double-blind placebo-controlled phase 2 dose-ranging study of onabotulinumtoxinA in men with benign prostatic hyperplasia. Eur Urol. 2012; 63(3):496-503. DOI: 10.1016/j.eururo.2012.10.005. View

11.

Purkiss J, Welch M, Doward S, Foster K . Capsaicin-stimulated release of substance P from cultured dorsal root ganglion neurons: involvement of two distinct mechanisms. Biochem Pharmacol. 2001; 59(11):1403-6. DOI: 10.1016/s0006-2952(00)00260-4. View

12.

Aoki K, Francis J . Updates on the antinociceptive mechanism hypothesis of botulinum toxin A. Parkinsonism Relat Disord. 2011; 17 Suppl 1:S28-33. DOI: 10.1016/j.parkreldis.2011.06.013. View

13.

Berry S, Coffey D, Walsh P, EWING L . The development of human benign prostatic hyperplasia with age. J Urol. 1984; 132(3):474-9. DOI: 10.1016/s0022-5347(17)49698-4. View

14.

Abrams P . Re: Update on AUA guideline on the management of benign prostatic hyperplasia: K. T. McVary, C. G. Roehrborn, A. L. Avins, M. J. Barry, R. C. Bruskewitz, R. F. Donnell, H. E. Foster, Jr., C. M. Gonzalez, S. A. Kaplan, D. F. Penson, J. C. Ulchaker.... J Urol. 2011; 187(1):358-9. DOI: 10.1016/j.juro.2011.09.020. View

15.

McVary K, Razzaq A, Lee C, Venegas M, Rademaker A, McKenna K . Growth of the rat prostate gland is facilitated by the autonomic nervous system. Biol Reprod. 1994; 51(1):99-107. DOI: 10.1095/biolreprod51.1.99. View

16.

Nalysnyk L, Papapetropoulos S, Rotella P, Simeone J, Alter K, Esquenazi A . OnabotulinumtoxinA muscle injection patterns in adult spasticity: a systematic literature review. BMC Neurol. 2013; 13:118. PMC: 3848723. DOI: 10.1186/1471-2377-13-118. View

17.

McVary K, McKenna K, Lee C . Prostate innervation. Prostate Suppl. 1998; 8:2-13. View

18.

Dolly J, Aoki K . The structure and mode of action of different botulinum toxins. Eur J Neurol. 2006; 13 Suppl 4:1-9. DOI: 10.1111/j.1468-1331.2006.01648.x. View

19.

Crawford E, Hirst K, Kusek J, Donnell R, Kaplan S, McVary K . Effects of 100 and 300 units of onabotulinum toxin A on lower urinary tract symptoms of benign prostatic hyperplasia: a phase II randomized clinical trial. J Urol. 2011; 186(3):965-70. PMC: 3601655. DOI: 10.1016/j.juro.2011.04.062. View

20.

Wang J, McKenna K, McVary K, Lee C . Requirement of innervation for maintenance of structural and functional integrity in the rat prostate. Biol Reprod. 1991; 44(6):1171-6. DOI: 10.1095/biolreprod44.6.1171. View